Prognostic Role of C-Reactive Protein in Urological Cancers: A Meta-Analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhou, Liang ^a   Cai, Xiang ^a   Liu, Qiang ^a   Jian, Zhong Yu ^a   Li, Hong ^a   Wang, Kun Jie ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

BLOOD; HUMAN; META ANALYSIS; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS; URINARY TRACT TUMOR;

BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS;

EID: 84938510356     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12733     Document Type: Article

References (66)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. Int J Cancer 127, 2893-2917 (2010).
2. Soerjomataram, I. et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380, 1840-1850 (2012).
3. Bex, A. et al. Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. Eur Urol 58, 819-828 (2010).
4. Cancer Research UK. Cancer Statistics Report: Cancer Incidence and Mortality in the UK. (2014) Available at: www. cancerresearchuk.org. (Accessed: 4th October 2014)
5. Eisenberg, M. S. et al. The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. J Urol 190, 2005-2010(2013).
6. Mantovani, A., Allavena, P., Sica, A., Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
7. Allavena, P., Sica, A., Solinas, G., Porta, C., Mantovani, A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66, 1-9 (2008).
8. Diakos, C. I., Charles, K. A., McMillan, D. C., Clarke, S. J. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15, e493-503(2014).
9. van Leeuwen, M. A. et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 21, 425-429 (1994).
10. Saito, K., Kihara, K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 20, 161-171 (2013).
11. Hu, Q. et al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 32, e51-58 (2014).
12. Wu, Y. et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 137, 887-896 (2011).
13. Rocha, P. et al. Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis. Oncol Res Treat 37, 772-776 (2014).
14. McArdle, P. A. et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 77, 127-129 (2006).
15. Beer, T. M. et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Eesults from the ASCENT trial. Cancer 112, 2377-2383 (2008).
16. Nakashima, J. et al. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int 80, 129-133 (2008).
17. McArdle, P. A., Qayyum, T., McMillan, D. C. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol Int 84, 430-435 (2010).
18. Tomioka, A. et al. Nadir PSA and time to PSA progression predict overall survival in patients with metastatic prostate cancer. Eur Urol Suppl 9, 77 (2010).
19. Ito, M. et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 78, 1131-1135 (2011).
20. Ljungberg, B., Grankvist, K., Rasmuson, T. Serum Interleukin-6 in Relation to Acute-phase Reactants and Survival in Patients with Renal Cell Carcinoma. Eur J Cancer 33, 1794-1798 (1997).
21. Miyata, Y. et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 58, 161-164 (2001).
22. Ito, K. et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13, 1365-1370 (2006).
23. Vogl, U. M. et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Brit J Cancer 95, 691-698(2006).
24. Komai, Y., Saito, K., Sakai, K., Morimoto, S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99, 77-80 (2007).
25. Kawata, N. et al. How do symptoms have an impact on the prognosis of renal cell carcinoma? Int J Urol 15, 299-303 (2008).
26. Ramsey, S., Lamb, G. W., Aitchison, M., McMillan, D. C. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 101, 959-963 (2008).
27. Iimura, Y. et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181, 1004-1012 (2009).
28. Miyake, H., Kurahashi, T., Takenaka, A., Inoue, T. A., Fujisawa, M. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 27, 598-603(2009).
29. Saito, K. et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55, 1145-1153(2009).
30. Naya, Y. et al. Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. Urol Int 85, 30-36 (2010).
31. Hotta, K. et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Brit J Cancer 105, 1191-1196 (2011).
32. Komura, K. et al. Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma. Nutr Cancer 63, 908-915 (2011).
33. Kume, H. et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol 185, 1611-1614 (2011).
34. Ito, H. et al. C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC cancer 12, 337 (2012).
35. Kinoshita, H. et al. Prognostic factors of metastatic renal cell carcinoma patients with removed metastases: A multicenter study of 559 patients. J Urol 1), S726 (2012).
36. Steffens, S. et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC cancer 12, 399 (2012).
37. Beuselinck, B. et al. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int 114, 81-89 (2014).
38. Herrel, L. A. et al. Preoperative C-reactive protein combined with SSIGN score as an independent predictor of cancer-specific survival in patients with clear cell renal cell carcinoma. J Clin Oncol 1), S451 (2013).
39. Kamba, T. et al. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice. Int J Clin Oncol 19, 505-515 (2014).
40. Kruck, S. et al. Use of preoperative C-reactive protein to improve predictive accuracy in clear cell renal cell carcinoma. J Clin Oncol 1), S457 (2013).
41. Kumano, M., Miyake, H., Harada, K., Fujisawa, M. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors. Med Oncol 30, 745-753 (2013).
42. Kwon, W. A. et al. Validation of the mskcc and heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. Ann Surg Oncol 20, 4397-4404 (2013).
43. Naito, S. et al. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82, 846-851 (2013).
44. Sakai, I., Miyake, H., Hinata, N., Fujisawa, M. Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol 19, 674-678 (2014).
45. Shinohara, N. et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol 31, 1276-1282 (2013).
46. Yasuda, Y. et al. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18, 884-889 (2013).
47. Hilmy, M. et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Brit J Cancer 95, 1234-1238(2006).
48. Saito, K. et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100, 269-273 (2007).
49. Yoshida, S. et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 101, 978-981 (2008).
50. Morizane, S. et al. Significance of hemoglobin value before gemcitabine/cisplatin or carboplatin treatment as an independent prognostic biomarker in advanced urothelial cancer. Urology 1), S394 (2011).
51. Eggers, H. et al. Serum C-reactive protein: A prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 30, 705 (2013).
52. Nakagawa, T. et al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J Urol 189, 1275-1281 (2013).
53. Sakano, S. et al. Risk group stratification based on preoperative factors to predict survival after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Ann Surg Oncol 20, 4389-4396 (2013).
54. Stein, B. et al. Preoperative serum C-reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC cancer 13, 101 (2013).
55. Kramer, M. W. et al. [C-reactive protein prior to radical cystectomy: preoperative determination of CRP]. Der Urologe. Ausg. A 53, 222-227 (2014).
56. Nakagawa, T. et al. Cancer-specific survival in patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy: External validation of the prognostic risk stratification model. J Clin Oncol 1), S325 (2014).
57. Tanaka, N. et al. The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study. Eur Urol 65, 227-234 (2014).
58. Ramsey, S., Lamb, G. W., Aitchison, M., Graham, J., McMillan, D. C. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109, 205-212 (2007).
59. Guthrie, G. J., Roxburgh, C. S., Horgan, P. G., McMillan, D. C. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39, 89-96(2013).
60. Kushner, I. The phenomenon of the acute phase response. Ann N Y Acad Sci 389, 39-48 (1982).
61. Trichopoulos, D., Psaltopoulou, T., Orfanos, P., Trichopoulou, A., Boffetta, P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15, 381-384 (2006).
62. Kinoshita, T., Ito, H., Miki, C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85, 2526-2531 (1999).
63. Okamoto, M., Hattori, K., Oyasu, R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. International journal of cancer. Int J Cancer 72, 149-154 (1997).
64. Johnson, T. V. et al. Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma. J Urol 186, 1213-1217 (2011).
65. Gueron, G., De Siervi, A., Vazquez, E. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15, 213-221(2012).
66. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283, 2008-2012 (2000).